Adjunctive armodafinil for major depressive episodes associated with bipolar i disorder

Journal of Affective Disorders

Volumn 181, Issue , 2015, Pages 87-91

  Ketter, Terence A ^a   Yang, Ronghua ^b   Frye, Mark A ^c  

^a STANFORD UNIVERSITY   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c MAYO CLINIC   (United States)

Author keywords

Armodafinil; Bipolar I disorder; Major depressive episodes

Indexed keywords

ARIPIPRAZOLE; ARMODAFINIL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PLACEBO; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ANTIDEPRESSANT AGENT; BENZHYDRYL DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; HYPOMANIA; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCORING SYSTEM; SOMNOLENCE; SUICIDAL IDEATION; TOOTH PAIN; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84929455230     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.04.012     Document Type: Article

References (27)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Text Revision: DSM-IV-TR 4th ed. 2000 American Psychiatric Association Washington, DC
2. C.H. Bastien, A. Vallieres, and C.M. Morin Validation of the Insomnia Severity Index as an outcome measure for insomnia research Sleep Med. 2 4 2001 297 307
3. J.R. Calabrese, M.A. Frye, R. Yang, T.A. Ketter, and Armodafinil Treatment Trial Study Network Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial J. Clin. Psychiatry 75 10 2014 1054 1061
4. J.R. Calabrese, R.M. Hirschfeld, M.A. Frye, and M.L. Reed Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample J. Clin. Psychiatry 65 11 2004 1499 1504
5. J.R. Calabrese, R.F. Huffman, R.L. White, S. Edwards, T.R. Thompson, J.A. Ascher, E.T. Monaghan, and R.A. Leadbetter Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials Bipolar Disord. 10 2 2008 323 333
6. J.R. Calabrese, P.E. Keck Jr., W. Macfadden, M. Minkwitz, T.A. Ketter, R.H. Weisler, A.J. Cutler, R. McCoy, E. Wilson, and J. Mullen A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry 162 7 2005 1351 1360
7. J.R. Calabrese, T.A. Ketter, J.M. Youakim, J.M. Tiller, R. Yang, and M.A. Frye Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study J. Clin. Psychiatry 71 10 2010 1363 1370
8. M.B. First, J.B.W. Williams, R.L. Spitzer, and M. Gibbon Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT) 2007 Biometrics Research, New York State Psychiatric Institute New York
9. K.N. Fountoulakis, S. Kasper, O. Andreassen, P. Blier, A. Okasha, E. Severus, M. Versiani, R. Tandon, H.J. Moller, and E. Vieta Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry Eur. Arch. Psychiatry Clin. Neurosci. 262 Suppl. 1 2012 S1 S48
10. M.A. Frye, H. Grunze, T. Suppes, S.L. McElroy, P.E. Keck Jr., J. Walden, G.S. Leverich, L.L. Altshuler, S. Nakelsky, S. Hwang, J. Mintz, and R.M. Post A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression Am. J. Psychiatry 164 8 2007 1242 1249
11. J.R. Geddes, J.R. Calabrese, and G.M. Goodwin Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Br. J. Psychiatry 194 1 2009 4 9
12. Hamilton Anxiety Rating Scale, 2011. UF MedConsults. Available at: http://dcf.psychiatry.ufl.edu/files/2011/05/HAMILTON-ANXIETY.pdf. (accessed 30.03.15.).
13. T.A. Ketter Handbook of Diagnosis and Treatment of Bipolar Disorder 2010 American Psychiatric Publishing, Inc. Washington, DC
14. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, J. Hsu, K. Sarma, and G. Sachs Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 171 2 2014 160 168
15. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, K. Sarma, J. Xu, and J.R. Calabrese Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 171 2 2014 169 177
16. I. Lombardo, G. Sachs, S. Kolluri, C. Kremer, and R. Yang Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J. Clin. Psychopharmacol. 32 4 2012 470 478
17. Nuvigil [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.
18. K. Posner, D. Brent, C. Lucas, M. Gould, B. Stanley, G. Brown, P. Fisher, J. Zelazny, A. Burke, M. Oquendo, and J. Mann Columbia-Suicide Severity Rating Scale (C-SSRS) Since Last Visit Available at: 2009 Columbia University Medical Center New York, NY http://www.cssrs.columbia.edu/docs/C-SSRS-1-14-09-Since-Last-Visit-Clinical.pdf (accessed 30.03.15.)
19. R.M. Post, K.D. Denicoff, G.S. Leverich, L.L. Altshuler, M.A. Frye, T.M. Suppes, A.J. Rush, P.E. Keck Jr., S.L. McElroy, D.A. Luckenbaugh, C. Pollio, R. Kupka, and W.A. Nolen Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method J. Clin. Psychiatry 64 6 2003 680 690
20. A.J. Rush, T. Carmody, and P.E. Reimitz The inventory of depressive symptomatology (IDS): clinician (C-IDS) and self-report (IDS-SR) ratings of depressive symptoms Int. J. Methods Psychiatr. Res. 9 2 2000 45 59
21. A.J. Rush, M.H. Trivedi, H.M. Ibrahim, T.J. Carmody, B. Arnow, D.N. Klein, J.C. Markowitz, P.T. Ninan, S. Kornstein, R. Manber, M.E. Thase, J.H. Kocsis, and M.B. Keller The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression Biol. Psychiatry 54 5 2003 573 583
22. G.S. Sachs, K.S. Ice, P.B. Chappell, J.H. Schwartz, O. Gurtovaya, D.G. Vanderburg, and B. Kasuba Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial J. Clin. Psychiatry 72 10 2011 1413 1422
23. M.M. Sidor, and G.M. MacQueen Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis J. Clin. Psychiatry 72 2 2011 156 167
24. M.E. Thase, A. Jonas, A. Khan, C.L. Bowden, X. Wu, R.D. McQuade, W.H. Carson, R.N. Marcus, and R. Owen Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies J. Clin. Psychopharmacol. 28 1 2008 13 20
25. M.E. Thase, W. Macfadden, R.H. Weisler, W. Chang, B. Paulsson, A. Khan, and J.R. Calabrese Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J. Clin. Psychopharmacol. 26 6 2006 600 609
26. M. Tohen, E. Vieta, J. Calabrese, T.A. Ketter, G. Sachs, C. Bowden, P.B. Mitchell, F. Centorrino, R. Risser, R.W. Baker, A.R. Evans, K. Beymer, S. Dube, G.D. Tollefson, and A. Breier Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch. Gen. Psychiatry 60 11 2003 1079 1088
27. R.C. Young, J.T. Biggs, V.E. Ziegler, and D.A. Meyer A rating scale for mania: reliability, validity and sensitivity Br. J. Psychiatry 133 1978 429 435